Woodstock Corp Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

Woodstock Corp reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,453 shares of the company's stock after selling 3,652 shares during the quarter. Johnson & Johnson comprises about 1.2% of Woodstock Corp's investment portfolio, making the stock its 24th biggest position. Woodstock Corp's holdings in Johnson & Johnson were worth $12,214,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. International Assets Investment Management LLC lifted its stake in Johnson & Johnson by 20,130.0% in the third quarter. International Assets Investment Management LLC now owns 3,454,473 shares of the company's stock worth $559,832,000 after purchasing an additional 3,437,397 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Johnson & Johnson by 506.9% during the 2nd quarter. Marshall Wace LLP now owns 3,884,962 shares of the company's stock worth $567,826,000 after acquiring an additional 3,244,862 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock valued at $549,223,000 after acquiring an additional 2,356,359 shares during the period. Franklin Resources Inc. grew its position in Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after acquiring an additional 1,729,281 shares during the last quarter. Finally, Holocene Advisors LP purchased a new stake in Johnson & Johnson in the third quarter worth $225,040,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 0.5 %

Shares of JNJ traded down $0.74 during mid-day trading on Friday, hitting $147.03. 10,678,393 shares of the company traded hands, compared to its average volume of 6,880,262. The business has a 50 day moving average of $148.51 and a 200 day moving average of $156.03. The company has a market capitalization of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.37%. Johnson & Johnson's payout ratio is presently 71.78%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on JNJ. Guggenheim upped their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a report on Wednesday, November 6th. StockNews.com lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target for the company. Wells Fargo & Company raised their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $174.29.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.